Phathom Pharmaceuticals(US:PHAT) Globenewswire·2026-01-07 21:01Core Insights - Phathom Pharmaceuticals, Inc. reported preliminary unaudited financial results for Q4 and full year 2025, indicating significant revenue growth and operational milestones [1][6]. Group 1: Preliminary Financial Results - For Q4 2025, Phathom expects net revenues of approximately $57 million to $58 million, with GAAP operating expenses of approximately $59 million to $61 million and non-GAAP operating expenses of approximately $51 million to $53 million, excluding about $8 million of stock-based compensation [8]. - For the full year 2025, net revenues are anticipated to be around $174.5 million to $175.5 million, with GAAP operating expenses of approximately $315.5 million to $317.5 million and non-GAAP operating expenses of approximately $284.5 million to $286.5 million, excluding about $31 million of stock-based compensation [8]. Group 2: Product Milestones - Phathom surpassed one million prescriptions dispensed for VOQUEZNA products in the U.S. since its launch during Q4 2025 [4]. Group 3: Future Outlook - The company anticipates achieving operating profitability in the second half of 2026, excluding stock-based compensation [5].